VivoSeq
Other

Magnetic Resonance Imaging (MRI)

0

Pipeline Programs↗

3

Active Trials↗

7

Companies Involved↗

Magnetic Resonance Imaging (MRI) is an early-stage landscape with 0 programs across 7 companies. The most active players are Shanghai Shengdi Pharmaceutical Co., Ltd, Bayer, Pfizer's Upjohn has merged with Mylan to form Viatris Inc..

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

96/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Shanghai Shengdi Pharmaceutical Co., Ltd

2 programs

Phase 3Bayer logo

Bayer

0 programs

PreclinicalP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

0 programs

PreclinicalEMD Serono logo

EMD Serono

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

29

clinical trials

Completed25 · 86%
Recruiting2 · 7%
Not yet recruiting1 · 3%
Terminated1 · 3%

Clinical Trials

Trial Activity

29 trials

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
Recruiting·IIvan de Kouchkovsky, MD·Phase 2·NCT06384222·32 enrolled
20 000 Lieues Sous l'IRM - New Simulation Care Pathway for Paediatric MRI Preparation : Exploratory Descriptive Pilot Study
Recruiting·NNantes University Hospital·N/A·NCT07344753·114 enrolled
A Study for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Not yet recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 2·NCT06731829·78 enrolled
Effect of Aromatase Inhibitors on Breast Magnetic Resonance Imaging (MRI)
Completed·MMount Sinai Hospital, Canada·Phase 2·NCT01129622·16 enrolled
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI)
Completed·Bayer logoBayer·Phase 3·NCT01104584·460 enrolled
Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Completed·GGuerbet·Phase 3·NCT03996447·260 enrolled
Study to Investigate Effect of Sildenafil on Clitoral Engorgement as Measured by Magnetic Resonance Imaging (MRI) in Pre-menopausal Women With Female Sexual Arousal Disorder
Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 2·NCT00640458·20 enrolled
Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients
Completed·Bayer logoBayer·Phase 3·NCT00395460·147 enrolled
Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain
Completed·BBracco Diagnostics, Inc·Phase 4·NCT01613417·229 enrolled
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
Completed·EMD Serono logoEMD Serono·Phase 4·NCT01085318·38 enrolled
The Effect of L-lysine on Human Gastrointestinal Secretion: A Dose-finding Study Applying Magnetic Resonance Imaging (MRI)
Completed·UUniversity of Zurich·N/A·NCT01579799·6 enrolled
Contrast-enhanced Ultrasound (CE-US) and Magnetic Resonance Imaging (MRI): Evaluating Plaque Neovascularisation
Completed·MMaastricht University Medical Center·N/A·NCT00677963·18 enrolled
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
Completed·GGuerbet·Phase 2·NCT02633501·312 enrolled
Magnetic Resonance Imaging (MRI) Assessments of the Heart and Liver Iron Load in Patients With Transfusion Induced Iron Overload
Completed·Novartis logoNovartis·Phase 4·NCT00673608·118 enrolled
A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children
Completed·Bayer logoBayer·Phase 1·NCT00468819·140 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)